Because PI3K/Akt and ERK pathways can regulate prostate cancer survival through the AR pathway, we investigated whether inhibiting PI3K/Akt and ERK pathways by kinase-specific inhibitors could affect AR phosphorylation. Here, AKT1 is linked to prostate cancer.